Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Crl
  6. /
  7. Aft Pharmaceuticals Ltd
CRL
•Aft Pharmaceuticals Ltd

Aft Pharmaceuticals Ltd – FDA CRL

Record Details

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to AFT Pharmaceuticals, Ltd. regarding their New Drug Application (NDA) for COMBOGESIC (ibuprofen 97.5 mg/acetaminophen 325 mg) Film-Coated Tablets, submitted under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. The application was not approved due to multiple deficiencies across clinical, statistical, nonclinical, product quality, and manufacturing facility aspects. Key issues included insufficient description of product exposure in clinical studies and inadequate quality of statistical datasets for Study AFT-MX-6, hindering efficacy confirmation. Nonclinical concerns involved inadequate justification for a drug substance specification linked to chromosomal aberrations and a failure to address elemental impurities in accordance with ICH Q3D guidance. Product quality deficiencies cited illegible analytical chromatograms, unsupported total impurity acceptance limits, missing regulatory specifications for release and stability, and lack of BSE/TSE certification for an excipient. Additionally, the company referred to non-commercial scale batches as validation batches, requiring validation at full commercial scale per FDA guidance. A significant issue was an unsatisfactory inspection at a manufacturing facility (COG), where product/process controls, lab controls, and quality assurance functions were found unacceptable. To address these, AFT Pharmaceuticals must provide detailed exposure data, re-analyze efficacy datasets, revise drug substance specifications, conduct elemental impurity analysis, update analytical procedures and specifications, provide excipient certifications, confirm commercial-scale process validation, resolve all facility observations, and submit a comprehensive safety update.

Company
Aft Pharmaceuticals Ltd
Product type
Drugs
Office
Office of Drug Evaluation II
Person
  • David Zuchero, MS, JD
View Company Profile

ID · 21e4ef77-306d-4552-964c-c95944585fe5

Other documents for Aft Pharmaceuticals Ltd
  • CRL
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Aft Pharmaceuticals Ltd
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.